12-year-old is happy to be testing COVID-19 vaccine at Cincinnati Children’s Hospital – WISH-TV | Indianapolis News | Indiana Weather

(CNN) — The youngest volunteers so far to get experimental coronavirus vaccines have been given their first doses and are now being watched carefully to see if they are experiencing any unusual side effects.

A team at Cincinnati Children’s Hospital vaccinated 100 children as young as 12 last week, said Dr. Robert Frenck, who is leading the trial for Pfizer’s COVID-19 vaccine at the hospital. “Now we are pausing to watch for reactions to the vaccine. We right now are in a planned pause to make sure that everything is as safe as it can be,” Frenck told CNN.

Among the side effects doctors are watching for are lumps, redness or pain at the site of the injection, as well as fever or aches.

Abhinav, 12, is one of the young volunteers. The seventh-grader — whose parents asked that only his first name be used to protect his privacy —

Read More

Covid-19 Vaccine Makers See Egypt as Crucial Launchpad

Egypt is emerging as a critical proving ground for global powers seeking to export a coronavirus vaccine to the developing world.

Its population of nearly 100 million, vaccine-manufacturing capacity and strategic location have made it an appealing platform for Russian, Chinese and Western vaccine makers.

Chinese officials have said they want to make Egypt a hub for manufacturing vaccines for the African market, with a state-run drugmaker having launched a partnership with the country to conduct human trials. Meanwhile, a private Egyptian company has agreed to import tens of millions of vaccine doses in a deal with Russia’s sovereign-wealth fund.

Egypt has also been in talks to import millions of doses of the vaccine being developed by researchers at the University of Oxford in partnership with



All of the deals are pending approval from Egypt’s regulators. The Health Ministry didn’t respond to requests for comment on the vaccines.

Read More

Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers.

Text size

Gilead’s antiviral drug remdesivir received marketing approval Thursday from the U.S. Food and Drug Administration as a treatment for Covid-19.

Justin Sullivan/Getty Images

The antiviral drug remdesivir received marketing approval Thursday from the U.S. Food and Drug Administration as a Covid-19 treatment. For

Gilead Sciences,

which will market the drug under the brand name Veklury, the sales of the drug could help the company get through a period of increasing competition for its products treating HIV and hepatitis.

Gilead stock (ticker: GILD) was up about 4% Friday after the news, to a level around $63.

The FDA gave Veklury a broad approval, allowing its use in patients over the age of 12 who are hospitalized with Covid-19. A study published in October in The New England Journal of Medicine found that the drug reduced recovery times for hospitalized patients from an average of 15 days to 10.

Read More

Regulators, experts take up thorny vaccine study issues


FILE – In this July 27, 2020, file photo, Nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. The U.S. Food and Drug Administration will hold a meeting to discuss the process of approving COVID-19 vaccines.


The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.

The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.

“We will not cut corners, and we will only use science and data to make that determination,” FDA

Read More

News Updates: AstraZeneca Vaccine Trial Death, Stimulus Talks Continue to Move Forward

Stefani Reynolds/Getty Images

Text size

Here’s what you need to know about the impact of Covid-19 to navigate the markets today.

Brazilian health officials said Wednesday that a participant in the trial of possible Covid-19 vaccine developed by AstraZeneca and Oxfored University has died. Testing of the vaccine in Brazil will continue, the country’s health authority Anvisa said. Further details about the participant or the cause of death weren’t provided because of medical confidentiality, Anvisa said.


stock turned negative and is down 0.4% on the news.

Trials of the possible AstraZeneca vaccine were previously halted after a participant in the U.K developed a serious medical condition but have restarted in Europe and Brazil. The U.S. may restart trials as early as this week, according to a Reuters report Tuesday.

House Speaker Nancy Pelosi said Wednesday afternoon that she is “pretty happy” about the state of negotiations

Read More

News Updates: Pfizer Sets Up “Biggest Ever” Distribution Campaign for Covid-19 Vaccine

Jeenah Moon/Getty Images

Text size

Here’s what you need to know about the impact of Covid-19 to navigate the markets today.

Drug giant Pfizer (ticker: PFE) has set up what it is calling its “biggest ever” logistics operation to distribute its Covid-19 vaccine once it receives emergency authorization from regulators, The Wall Street Journal reports. The pharmaceutical company has plans to deliver up to 100 million doses this year and another 1.3 billion next year.


logistics preparation reflects its desire to move as quickly as possible to get vaccine doses into the population once it gets the nod from the Food and Drug Administration. Pfizer’s possible vaccine is being developed in partnership with German-based


(BNTX) and is currently in Phase 3 trials. Data showing whether it is safe and effective might be available as early as the end of this month, setting the company up to

Read More

Maryland coronavirus plan says 14 percent of residents eligible for early vaccine when available

Maryland’s 68-page plan aims to “immediately make the vaccine available to Marylanders at highest risk of developing complications from COVID-19 as well as our critical front line health care workers and essential workers in public safety and education,” Gov. Larry Hogan (R) said in a news release.

High-risk health-care workers, first responders, older adults in congregate settings, incarcerated people and people with comorbidities and underlying conditions will be eligible for a vaccine during the first of two phases of distribution.

The plan outlines 13 focus areas, including an estimate of critical populations, vaccine provider recruitment and enrollment, and how health officials plan to ensure residents a vaccine is safe and effective.

According to the plan, residents will use the website to preregister for the vaccine, and providers will use an online immunization database to order vaccines and to track their delivery and the doses administered.

Maryland began discussing vaccine

Read More

Hesitancy about a COVID-19 vaccine is linked to beliefs about origin of the virus

Hesitancy about a COVID-19 vaccine is linked to beliefs about origin of the virus
Percentage of participants who responded “yes” to the question of whether they would vaccinate themselves and their children for COVID-19 in Turkey (n= 3936) and the UK (n= 1088) based on their belief on the origin of the coronavirus (artificial / not sure / natural). (from the study). Credit: Cambridge University Press

More than a third of people (34%) in Turkey and one sixth of people (17%) in the UK are ‘hesitant’ about a COVID-19 vaccine, according to a study by UCL and Dokuz Eylul University in Turkey.

The research, published in the journal Psychological Medicine, asked over 5,000 participants in Turkey and the UK about their willingness to vaccinate for a potential COVID-19 vaccine and beliefs on the origin of the novel coronavirus. The findings show concerning levels of COVID-19 vaccine hesitancy.

Lead author, Dr. Gul Deniz Salali, an evolutionary anthropologist at UCL, said: “From an evolutionary point

Read More

We’re All Waiting For A COVID-19 Vaccine. For Kids, The Wait May Be Much Longer.

COVID-19 cases are surging again in the United States as experts warn of a “third peak” that could be particularly devastating while much of the country rides out the winter indoors.

Even if case counts begin to fall, there’s no real chance of life getting back to anything close to normal until a COVID-19 vaccine is available. And until a vaccine is available for kids, there’s little chance of families settling back into functioning routines.

Unfortunately, experts seem to agree that it’s unlikely a vaccine for COVID-19 in children will be available as soon as one (or several) is available for adults. Some are predicting we will not get a vaccine for kids until next fall.

That’s not an easy prediction to hear as a parent. But grappling with that extended timeline — however theoretical it may be — can influence the decisions parents are making right now as they

Read More

Overnight Health Care: Pfizer could apply for vaccine authorization by late November | State health officials say they need $8.4B for vaccination effort | CDC: Blacks, Hispanics dying of COVID-19 at disproportionately high rates

Welcome to Friday’s Overnight Health Care.

The CDC released new data showing people of color are dying of COVID-19 at disproportionately high rates. State health officials tell Congress they need more money for vaccine distribution. And NARAL, a pro-choice group is calling for new Democratic leadership on the Senate Judiciary Committee after the top Democrat on the panel Sen. Diane Feinstein (Calif.) praised the proceedings surrounding Amy Coney BarrettAmy Coney BarrettSix takeaways from Trump and Biden’s dueling town halls Biden draws sharp contrast with Trump in low-key town hall Trump fields questions on coronavirus, conspiracy theories in combative town hall MORE’s confirmation. 

Let’s start with some vaccine news: 

Pfizer could apply for US emergency use approval for coronavirus vaccine by late November

It’s now looking even more likely that there will not be a coronavirus vaccine before Election Day, a goal that always faced tough odds for success.  

Read More